Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | AGER | Q15109 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29551359 | 1.00 | MYC (0.57) | MYCKDM4ETDP1CAPN1LMNA | |
| SCHEMBL5663804 | 0.87 | CAPN1 (0.55) | MYCKDM4ETDP1CAPN1LMNA | |
| SCHEMBL16544035 | 0.87 | HCRTR2 (0.49) | MYCKDM4ETDP1CAPN1LMNA | |
| SCHEMBL29551168 | 0.87 | CAPN1 (0.55) | MYCKDM4ETDP1CAPN1LMNA | |
| SCHEMBL14232737 | 0.83 | HCRTR2 (0.52) | MYCCAPN1LMNAKMT2AHCRTR2 | |
| SCHEMBL19564476 | 0.83 | CAPN1 (0.49) | MYCCAPN1LMNAKMT2AHCRTR2 | |
| SCHEMBL17793767 | 0.80 | MYC (0.54) | MYCKDM4ETDP1LMNAKMT2A | |
| SCHEMBL29551344 | 0.79 | HCRTR2 (0.46) | MYCCAPN1LMNAHCRTR2HCRTR1 | |
| SCHEMBL17793835 | 0.79 | HCRTR1 (0.52) | KDM4ECAPN1ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL29551266 | 0.79 | HCRTR1 (0.52) | KDM4ECAPN1ALDH1A1TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114555556-B | Process for preparing CFTR modulators | 弗特克斯药品有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-10435398-B2 | Oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2019-10-08 | — | — | US | disclosed |
| US-10435398-B2 | Oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2019-10-08 | — | — | US | disclosed |
| US-10239838-B2 | Heteroaryl orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10239838-B2 | Heteroaryl orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180370973-A1 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-12-27 | — | — | US | disclosed |
| US-10150751-B2 | Pyrrolidine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-12-11 | — | — | US | disclosed |
| US-10011595-B2 | Ethyldiamine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011595-B2 | Ethyldiamine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-9987255-B2 | 5,5-bicyclic oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-05 | — | — | US | disclosed |
| WO-2016100156-A1 | HETEROARYL OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016089721-A1 | METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016089721-A1 | METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016086357-A1 | METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016088813-A1 | NOVEL DIAZABICYCLO[2.2.2]OCTANE DERIVATIVE | 持田製薬株式会社 | 2016-06-09 | — | — | WO | disclosed |
| WO-2016084866-A1 | NOVEL DIAZABICYCLO DERIVATIVE | 持田製薬株式会社 | 2016-06-02 | — | — | WO | disclosed |
| WO-2016065583-A1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016069515-A1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| EP-1337251-A1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002102380-A1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370973-A1 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | MYC 4321/4885KDM4E 2571/4885TDP1 4734/4885 |
| US-10150751-B2 | Pyrrolidine orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | MYC 4811/4885KDM4E 1612/4885TDP1 4130/4885 |
| US-10435398-B2 | Oxazole orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | MYC 4850/4885KDM4E 2264/4885TDP1 4549/4885 |
| US-10239838-B2 | Heteroaryl orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | MYC 4428/4885KDM4E 2387/4885TDP1 4648/4885 |
| US-10011595-B2 | Ethyldiamine orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | MYC 4164/4885KDM4E 1681/4885TDP1 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.